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S U M M A R Y
Objectives: To separate Mycobacterium abscessus subsp. bolletii from Mycobacterium abscessus subsp.
abscessus using species identiﬁcation, and to investigate the in vitro activity of amikacin, cefoxitin,
imipenem, levoﬂoxacin, moxiﬂoxacin, clarithromycin, azithromycin, and linezolid against Mycobacteri-
um abscessus.
Methods: Seventy M. abscessus isolates, previously identiﬁed by 16S rRNA sequencing, were further
identiﬁed by comparative sequence analysis of rpoB and hsp65. Drug susceptibility testing was
conducted using the microplate Alamar Blue assay in accordance with Clinical and Laboratory Standards
Institute (CLSI) guidelines and interpreted using CLSI breakpoints.
Results: Of the 70 strains, 45 (64%) were M. abscessus subsp. abscessus and 25 (36%) were M. abscessus
subsp. bolletii. The majority of M. abscessus isolates were susceptible to azithromycin, amikacin, linezolid,
and imipenem (M. abscessus subsp. abscessus: 93%, 98%, 93%, and 73%, respectively; M. abscessus subsp.
bolletii: 96%, 96%, 80%, and 68%, respectively). Approximately half of the M. abscessus isolates were
moderately susceptible to cefoxitin and moxiﬂoxacin (M. abscessus subsp. abscessus 53% and 49%; M.
abscessus subsp. bolletii 72% and 68%). Nearly all the M. abscessus isolates were resistant to levoﬂoxacin
(M. abscessus subsp. abscessus 96%, M. abscessus subsp. bolletii 100%). Inducible clarithromycin resistance
was found in M. abscessus. After 14 days of incubation, 83% M. abscessus subsp. abscessus and 36% M.
abscessus subsp. bolletii were resistant to clarithromycin.
Conclusions: Using rpoB and hsp65, M. abscessus subsp. bolletii could be distinguished from M. abscessus
subsp. abscessus. Amikacin and azithromycin showed excellent activity against M. abscessus in vitro.
Imipenem, linezolid, cefoxitin, and moxiﬂoxacin also showed good activity. Levoﬂoxacin was inactive
against M. abscessus. Although clarithromycin showed excellent activity against M. abscessus on day 3,
inducible resistance occurred, and after 14 days clarithromycin showed little activity against M.
abscessus subsp. abscessus, but still had good activity against M. abscessus subsp. bolletii.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Non-tuberculous mycobacterial (NTM) disease in humans has
been recognized as an emerging public health problem.1,2 Drug
therapy of NTM disease is long, costly, and often associated with
drug-related toxicities, so the treatment of NTM disease, in
particular pulmonary NTM disease, can be disappointing; clinical* Corresponding author. Tel.: +86 13611326573; fax: +86 10 8950 9301.
E-mail address: dongchu1994@sina.com (N. Chu).
http://dx.doi.org/10.1016/j.ijid.2014.02.014
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).improvement and prolonged culture conversion is not achievable
for all patients.3 There are two kinds of NTM: rapidly growing
mycobacteria and slowly growing mycobacteria. Mycobacterium
abscessus is the most common etiological agent of lung disease
caused by rapidly growing mycobacteria.4–7M. abscessus is resistant
to many antibiotics in vitro,8,9 so the cure rate of pulmonary disease
is low, ranging from 30% to 50% in M. abscessus disease.3
In recent years, many novel NTM species have been discovered
through the increased application of genetic investigation tools,
and detailed genetic characterizations have helped deﬁne new
taxonomic groupings.10,11 Two new M. abscessus-related species,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Breakpoints of each drug, according to the CLSI recommendations.
MIC (mg/ml)
Antibiotic Susceptible
breakpoint
Moderately
susceptible
breakpoint
Resistant
breakpoint
Amikacin 16 32 64
Cefoxitin 16 32–64 128
Imipenem 4 8 16
Levoﬂoxacin 1 2 4
Moxiﬂoxacin 1 2 4
Clarithromycin 2 4 8
Azithromycin 16 32 64
Linezolid 8 16 32
CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory
concentration.
Table 2
Morphology of colonies; No. (%) of strains.
Subspecies Rough Smooth Total
M. abscessus subsp. abscessus 21 (47%) 24 (53%) 45 (100%)
M. abscessus subsp. bolletii 17 (68%) 8 (32%) 25 (100%)
Total 38 (54%) 32 (46%) 70 (100%)
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identiﬁed, which had previously been grouped with M. absces-
sus.12,13 Recently, it was proposed that M. massiliense and M. bolletii
should be Mycobacterium abscessus subsp. bolletii comb. nov., and
M. abscessus should be Mycobacterium abscessus subsp. abscessus
subsp. nov. The species description of M. abscessus is also emended
to cover both M. abscessus subsp. bolletii and M. abscessus subsp.
abscessus.
It is reported that M. abscessus subsp. abscessus and M. abscessus
subsp. bolletii infections may have different drug sensitivity test
(DST) results and clinical symptoms, and that their responses to
antibiotics vary from each other.14,15 Furthermore, a longer
incubation can lead to clarithromycin resistance, which has been
suggested as an explanation for the lack of efﬁcacy of clarithro-
mycin-based treatments. However, this inducible resistance has
not been found in M. abscessus subsp. bolletii.14 In China, isolate
species are usually identiﬁed using 16S rRNA sequencing; however
this method cannot distinguish M. abscessus subsp. abscessus from
M. abscessus subsp. bolletii.
In this study, 70 clinical M. abscessus isolates (previously
identiﬁed by 16S rRNA) were divided into M. abscessus subsp.
abscessus and M. abscessus subsp. bolletii using rpoB and hsp65
sequence analysis. The sensitivities to eight drugs, including
amikacin, cefoxitin, imipenem, levoﬂoxacin, moxiﬂoxacin, clari-
thromycin, azithromycin, and linezolid, were tested, and the
development of inducible resistance was investigated.
2. Materials and methods
2.1. Isolates, drugs, and other materials
All of the 70 M. abscessus clinical strains were isolated from
sputum samples of patients and had previously been identiﬁed as
M. abscessus to the species level using 16S rRNA gene sequencing at
the Reference Laboratory of Beijing Chest Hospital. The type strains
of ATCC19977 and CIP108297 were used for comparison. All the
strains were subcultured on Lowenstein–Jensen medium at 37 8C
for approximately 4–6 days to observe colony morphology and
were then used for species identiﬁcation based on rpoB and hsp65
sequence analysis. All the drugs, including amikacin, cefoxitin,
imipenem, levoﬂoxacin, moxiﬂoxacin, clarithromycin, azithromy-
cin, and linezolid, were purchased from Sigma–Aldrich Chemical
Co. Alamar blue was purchased from Serotec. OADC was purchased
from Becton Dickinson.
2.2. Genotypic identiﬁcation
DNA was extracted from cultured colonies using the boiling
method,16 and used as templates for PCR. The following primer
pairs were used: 5-GAC GAC ATC GAC CAC TTC GG-3 and 5-GGG
GTC TCG ATC GGG CAC AT-3 for rpoB PCR,17 and 5-ACC AAC GAT
GGT GTG TCC AT-3 and 5-CTT GTC GAA CCG CAT ACC CT-3 for
hsp65 PCR.18 Preparation of the PCR reaction mixture and
ampliﬁcation were done as described previously.17–20 PCR
products were puriﬁed and sequenced by the BGI Corporation
using forward and reverse primers. Both strands were sequenced
as a cross-check. Species identiﬁcation of these strains was
accomplished by the sequencing of rpoB and hsp65, using a BLAST
search to measure the similarities.
2.3. Susceptibility testing
Susceptibility testing to the study drugs was carried out in
accordance with the Clinical and Laboratory Standards Institute
(CLSI) recommendations. The ﬁnal drug concentrations tested
were as follows: amikacin 0.5 to 256 mg/ml, cefoxitin 0.5 to256 mg/ml, imipenem 0.25 to 128 mg/ml, levoﬂoxacin 0.125 to
64 mg/ml, moxiﬂoxacin 0.0625 to 32 mg/ml, clarithromycin 0.0625
to 32 mg/ml, azithromycin 0.5 to 256 mg/ml, and linezolid 0.25 to
128 mg/ml. Minimum inhibitory concentrations (MICs) of each
drug were determined by broth microdilution method, as
recommended by the CLSI, using 96-well plates21. For amikacin,
cefoxitin, imipenem, levoﬂoxacin, moxiﬂoxacin, azithromycin, and
linezolid, the MICs were determined after 3 days of incubation. For
clarithromycin, however, plates were submitted to an extended
incubation, with successive readings after 3, 5, 7, 9, and 14 days of
incubation at 30 8C. After incubation, Alamar blue dye was added
to each well and the plates were reincubated for 24 h. A color
change from blue to pink indicates bacterial growth. The MIC was
deﬁned as the lowest concentration of the drug that showed no
color change, which was the lowest concentration of drug capable
of inhibiting the visible growth of tested isolates. MIC50 and MIC90
values were deﬁned as drug concentrations that inhibited 50% and
90% of isolates, respectively. Susceptibility was evaluated accord-
ing to CLSI breakpoint recommendations (Table 1). Finally, the
proportions resistant were analyzed by Chi-square test or Fisher’s
exact test. A p-value of <0.05 indicates statistical signiﬁcance.
3. Results
The morphology of colonies was divided into two types, rough
and smooth. The proportions of rough and smooth for M. abscessus
subsp. abscessus were 47% and 53%, respectively, and for M.
abscessus subsp. bolletii were 68% and 32%, respectively (Table 2).
The proportions of rough and smooth were similar for M. abscessus
subsp. abscessus. However, for M. abscessus subsp. bolletii, the
proportion of smooth colonies was less than that of rough colonies.
There were no mixed colonies observed, although it is reported
that the morphology of colonies can be distinguished into three
types: rough, smooth, and mixed.19
Species identiﬁcation of these strains was accomplished by
BLAST search to measure the similarities. All of the 70 M. abscessus
isolates were divided into two subspecies: 45 (64%) were M.
abscessus subsp. abscessus isolates and 25 (36%) were M. abscessus
subsp. bolletii isolates.
Two methods were used in this test to identify subspecies: rpoB
and hsp65 gene sequencing. The results of these two methods were
Table 3
Results of susceptibility testing. The proportions of resistance of M. abscessus subsp. abscessus and M. abscessus subsp. bolletii were compared using the Chi-square test or
Fisher’s exact test.
Drug M. abscessus subspecies Incubation time MIC range
(mg/ml)
MIC50
(mg/ml)
MIC90
(mg/ml)
No. (%)
susceptible
No. (%)
moderately
susceptible
No. (%)
resistant
p-Value
Amikacin abscessus
(n = 45)
Day 3 1–32 4 8 44 (98%) 1 (2%) 0 (0%) 0.357
bolletii
(n = 25)
Day 3 2–64 4 8 24 (96%) 0 (0%) 1 (4%)
Cefoxitin abscessus
(n = 45)
Day 3 4–64 32 32 21 (47%) 24 (53%) 0 (0%) 0.357
bolletii
(n = 25)
Day 3 16–>256 32 32 6 (24%) 18 (72%) 1 (4%)
Imipenem abscessus
(n = 45)
Day 3 0.5–16 4 8 33 (73%) 9 (20%) 3 (7%) 0.201
bolletii
(n = 25)
Day 3 2–16 4 8 17 (68%) 4 (16%) 4 (16%)
Levoﬂoxacin abscessus
(n = 45)
Day 3 2–>64 8 32 0 (0%) 2 (4%) 43 (96%) 0.410
bolletii
(n = 25)
Day 3 4–>64 8 32 0 (0%) 0 (0%) 100 (100%)
Moxiﬂoxacin abscessus
(n = 45)
Day 3 1–4 2 2 19 (42%) 22 (49%) 4 (9%) 0.087
bolletii
(n = 25)
Day 3 1–4 2 4 2 (8%) 17 (68%) 6 (24%)
Azithromycin abscessus
(n = 45)
Day 3 0.5–128 4 8 42 (93%) 1 (2%) 2 (5%) 0.711
bolletii
(n = 25)
Day 3 0.5–64 1 4 24 (96%) 0 (0%) 1 (4%)
Linezolid abscessus
(n = 45)
Day 3 1–32 4 8 42 (93%) 2 (5%) 1 (2%) 0.590
bolletii
(n = 25)
Day 3 4–>128 8 16 20 (80%) 4 (16%) 1 (4%)
Clarithromycin abscessus Day 3 0.0625–2 0.125 0.5 45 (100%) 0 (0%) 0 (0%) 0.375
(n = 45) Day 5 0.25–>32 4 >32 17 (37%) 7 (16%) 21 (47%) 0.000
Day 7 0.5–>32 32 >32 10 (23%) 3 (7%) 32 (70%) 0.000
Day 9 1–>32 >32 >32 5 (10%) 3 (7%) 37 (83%) 0.000
Day 14 1–>32 >32 >32 5 (10%) 3 (7%) 37 (83%) 0.000
bolletii Day 3 0.0625–>32 0.125 0.25 24 (96%) 0 (0%) 1 (4%)
(n = 25) Day 5 0.0625–>32 0.125 0.25 24 (96%) 0 (0%) 1 (4%)
Day 7 0.0625–>32 0.125 0.25 24 (96%) 0 (0%) 1 (4%)
Day 9 0.0625–>32 0.25 0.25 24 (96%) 0 (0%) 1 (4%)
Day 14 0.0625–>32 0.25 0.25 24 (96%) 0 (0%) 1 (4%)
MIC, minimum inhibitory concentration.
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and M. abscessus subsp. bolletii strains divided by rpoB sequence
were veriﬁed by hsp65 sequence. There was no discordant result in
the rpoB and hsp65 sequence analyses. The rpoB similarities of M.
abscessus to the reference sequences were 98% to 100%, and the
hsp65 similarities were 98% to 100%.
The breakpoint, MIC range, MIC50, MIC90, and proportions of
susceptible, moderately susceptible, and resistant to each drug for
M. abscessus subsp. abscessus and M. abscessus subsp. bolletii are
shown in Table 3; susceptibility was evaluated in accordance with
CLSI breakpoint recommendations (Table 1). It can be seen that
most M. abscessus subsp. abscessus isolates were susceptible to
azithromycin, amikacin, linezolid, and imipenem (93%, 98%, 93%
and 73%, respectively). About half of the M. abscessus subsp.
abscessus isolates were moderately susceptible to cefoxitin and
moxiﬂoxacin (53% and 49%). Ninety-six percent of M. abscessus
subsp. abscessus isolates were resistant to levoﬂoxacin. Similar
results were obtained for M. abscessus subsp. bolletii. Most M.
abscessus subsp. bolletii isolates were susceptible to azithromycin,
amikacin, linezolid, and imipenem (96%, 96%, 80%, and 68%,
respectively). More than half of the M. abscessus subsp. bolletii
isolates were moderately susceptible to cefoxitin and moxiﬂoxacin
(72% and 68%). All of the M. abscessus subsp. bolletii isolates were
resistant to levoﬂoxacin. Comparing the proportions resistant
between M. abscessus subsp. abscessus and M. abscessus subsp.bolletii, all p-values were 0.05, and there was no signiﬁcant
difference between them.
With regard to clarithromycin, after repeated readings on days
3, 5, 7, 9, and 14, we saw an obvious increase in MIC50 and MIC90.
All 45 M. abscessus subsp. abscessus isolates had clarithromycin
MICs not exceeding 2 mg/ml when the broth susceptibility tests
were read on day 3, which means all of these isolates were
susceptible to clarithromycin. However, on days 5, 7, 9, and 14, the
M. abscessus subsp. abscessus isolates became increasingly resistant
to clarithromycin. On day 14, which is the shortest time the CLSI
recommends for a ﬁnal reading, the resistance rate was 83%. In
contrast, with the exception of one M. abscessus subsp. bolletii
isolate which had a MIC >32 mg/ml on day 3, clarithromycin MICs
of all of the remaining 24 M. abscessus subsp. bolletii isolates were
not more than 2 mg/ml when the broth susceptibility tests were
read on day 3 and they remained at 2 mg/ml during the 14-day
observation. Comparing the proportions resistant between M.
abscessus subsp. abscessus and M. abscessus subsp. bolletii, all p-
values were <0.05, and there was a signiﬁcant difference between
them.
4. Discussion
Nucleotide sequence information for the 16S rRNA genes and
internal transcribed spacer (ITS) gene has been used widely to ﬁnd
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gene and ITS gene sequence analysis fails to distinguish M.
abscessus subsp. bolletii from M. abscessus subsp. abscessus. In the
ﬁrst report on M. abscessus subsp. bolletii, because its 16S rRNA
gene sequence was identical to that of M. abscessus subsp.
abscessus, other gene sequences (hsp65, rpoB, etc.) were also
presented to demonstrate the genotype difference between the
two species.19 Thus, we applied hsp65 and rpoB gene sequence
analysis in the early stage of our study. Seventy isolates that had
previously been identiﬁed as M. abscessus using 16S rRNA could be
separated into M. abscessus subsp. abscessus and M. abscessus
subsp. bolletii. There are reports of discordant results between rpoB
and hsp65 analysis for some strains; this discordance can be
avoided by sequencing the additional sodA and the 16S–23S ITS.19
In our experiment, however, we did not observe any discordance.
All the subspecies identiﬁed by rpoB were the same as with hsp65.
For M. abscessus, the most notorious causative agent of disease
among the rapid growers, drug therapy of NTM disease is long,
costly, and often associated with drug-related toxicities.3 M.
abscessus is also resistant to many antibiotics in vitro,8,9 leading to
unsatisfactory treatment results. The 2007 ATS/IDSA (American
Thoracic Society/Infectious Diseases Society of America) guidelines
recommend 2–4 months of intravenous amikacin plus cefoxitin or
imipenem combined with clarithromycin or azithromycin, but
there is little concrete evidence supporting these guidelines; in fact
it was noted that a reliable antibiotic regimen that could cure M.
abscessus was not known.4 Macrolides are frequently the only oral
agents that are active in vitro against M. abscessus. We investigated
the susceptibility of M. abscessus to eight antibiotics in order to
evaluate their activity against the pathogen. Among these eight
antibiotics, amikacin, cefoxitin, clarithromycin, and azithromycin
are recommended key components for the treatment of M.
abscessus; levoﬂoxacin is one of the most frequently used
antibiotics in China; imipenem, linezolid, and moxiﬂoxacin are
more recent antibiotics that have previously been reported to have
probable activity against Mycobacterium.
As the key agents against M. abscessus, amikacin and
azithromycin expressed excellent activity in vitro in DST in the
current study. Imipenem, linezolid, and moxiﬂoxacin also showed
good activity in vitro against M. abscessus. As a key agent against M.
abscessus, compared with the antibiotics above, cefoxitin did not
show a high susceptible proportion. Fifty-three percent of M.
abscessus subsp. abscessus isolates and 72% M. abscessus subsp.
bolletii isolates were moderately susceptible to cefoxitin. Compar-
ing these results with other published data,14,15,19 the proportions
resistant to the drugs tested by DST in the current study are a little
lower than those of other countries. The reasons for this difference
may be as follows: Firstly, the isolates from different areas may
have different patterns. Secondly, in China our understanding of
NTM is only in the early stages. A large proportion of NTM patients
do not receive the appropriate treatment, so the isolates have
retained good susceptibility to the antibiotics to which these
organisms were originally susceptible. The proportion of M.
abscessus resistant to levoﬂoxacin was found to be high. Nearly
all the M. abscessus in this study were resistant to levoﬂoxacin. The
reasons for the high proportion of resistance may be as follows:
Firstly, ﬂuoroquinolones are overused in China, and some isolates
have already been exposed to these drugs, so isolate susceptibility
to levoﬂoxacin has been weakened. Secondly, some isolates are
naturally resistant to levoﬂoxacin.
It is reported that M. abscessus subsp. abscessus and M. abscessus
subsp. bolletii have different clinical characteristics and treatment
responses in vivo, and have different drug susceptibility in vitro.14,15
For instance, an experiment in Japan showed that bronchiectasia
may occur more frequently with M. abscessus subsp. abscessus than
with M. abscessus subsp. bolletii in vivo, and the proportion resistantto imipenem was lower in M. abscessus subsp. abscessus than in M.
abscessus subsp. bolletii.15 An experiment in Korea showed that M.
abscessus subsp. abscessus may have a worse radiographic response
on high-resolution computed tomography and worse microbiolog-
ical response than M. abscessus subsp. bolletii in vitro, and similarly,
the proportion resistant to imipenem was lower for M. abscessus
subsp. abscessus than M. abscessus subsp. bolletii.14
To our knowledge, this is the ﬁrst report from China comparing
the resistance to eight drugs between M. abscessus subsp. abscessus
and M. abscessus subsp. bolletii. However, with the exception of
clarithromycin, there was no signiﬁcant difference between the
subspecies in the proportions resistant to the remaining antibiotics
tested. We do not at present have the clinical data comparing the
two subspecies, so we should also undertake clinical research to
determine the difference between them in order to analyze the
necessity of separating the two.
In the 1990s, clarithromycin became the drug of choice for M.
abscessus infections and therapeutic successes were reported. The
macrolide clarithromycin is considered the cornerstone of
antimicrobial chemotherapy for pulmonary M. abscessus infec-
tions.4 It is the only drug with demonstrated efﬁcacy that can be
administered orally. Inducible resistance to clarithromycin has
been suggested as an explanation for the lack of efﬁcacy of
clarithromycin-based treatments against M. abscessus infection.24
The two main mechanisms of clarithromycin resistance are well
established. The ﬁrst comprises mutations in the drug-binding
pocket, in particular at nucleotide positions 2058 and 2059, of the
bacterial 23S rRNA gene.25–28 Corresponding mutations confer
high-level resistance to clarithromycin (MIC >256 mg/l) in
bacterial species with a limited number of chromosomal rRNA
operons, including Mycobacterium chelonae and M. abscessus.29–32
The second mechanism is conferred by a class of genes coding for
inducible erythromycin ribosomal methylases (Erm), which mono-
or dimethylate the adenine at position 2058 of the 23S rRNA.
However, this inducible macrolide resistance has not been found in
M. massiliense infection.14 Erm genes in subspecies of M. abscessus
show characteristic differences. Compared with its homologues in
M. abscessus subsp. abscessus, the Erm methylase in M. abscessus
subsp. bolletii is dysfunctional due to a 2-bp deletion of nucleotides
64–65 and a 274-bp deletion of nucleotides 159–432.24,33 Our
study demonstrated a signiﬁcantly higher level of inducible
resistance in response to clarithromycin in M. abscessus subsp.
abscessus isolates; although a strain might appear susceptible after
3 days of in vitro incubation, the strain may be clarithromycin-
resistant if incubation is extended to 14 days. All 45 of the M.
abscessus subsp. abscessus isolates that appeared to be susceptible
to clarithromycin on day 3 showed much higher MICs in the
following days. On day 14, 83% of M. abscessus isolates showed a
MIC of at least 8 mg/ml to clarithromycin, i.e., these isolates
developed in vitro resistance to clarithromycin. In contrast, with
the exception of one isolate that was resistant to clarithromycin on
day 3, all of the remaining 24 M. abscessus subsp. bolletii isolates
remained susceptible to clarithromycin during the 14-day
observation period. These ﬁndings may explain the signiﬁcant
difference in treatment outcomes between M. abscessus and M.
massiliense lung disease.
Consequently, from a clinical standpoint, this study has some
important therapeutic implications. The inducible resistance to
clarithromycin of M. abscessus subsp. abscessus isolates means that
it can be much more difﬁcult to treat M. abscessus subsp. abscessus
lung disease. A much longer duration of intravenous antibiotic
therapy and more effective oral antibiotics may be needed to
improve treatment outcomes in M. abscessus subsp. abscessus lung
disease. However, only rare drugs can be proposed as alternatives,
so the treatment of these infections is nearly impossible. The
M. abscessus subsp. bolletii low MIC for clarithromycin and the
W. Nie et al. / International Journal of Infectious Diseases 25 (2014) 170–174174absence of inducible resistance to clarithromycin suggest that M.
abscessus subsp. bolletii lung disease may be more effectively
treated with a clarithromycin-based antibiotic regimen.14
Although levoﬂoxacin and moxiﬂoxacin are both ﬂuoroquino-
lone antibiotics, distinctly different proportions of M. abscessus
were resistant. The proportion resistant to levoﬂoxacin was much
higher than that resistant to moxiﬂoxacin. The reasons for this
difference may be as follows: (1) some M. abscessus isolates are
naturally resistant to levoﬂoxacin and susceptible to moxiﬂoxacin;
(2) levoﬂoxacin is used much more widely and for longer than
moxiﬂoxacin, so overexposure to levoﬂoxacin reduces its activity
against the isolates. However, with regard to the macrolides,
clarithromycin and azithromycin showed similar activity in this
study, and both had excellent activity against M. abscessus.
The exact role of DST remains the subject of debate. One of the
reasons for this is that there are important discrepancies between
drug susceptibility measured in vitro and the activity of the drug
observed in vivo. These discrepancies derive in part from
laboratory technical difﬁculties in DST, standardization of meth-
ods, and a lack of clinical validation. The question of how to assess
the signiﬁcance of DST results in relation to clinical treatment
needs to be analyzed carefully.
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